飞速体育cba:
Immunity.
2016 Sep 20;45(3):555-69. doi: 10.1016/j.immuni.2016.08.014. Epub 2016 Sep 13.
飞速体育cba:Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate theKinetics of Response to DNA Virus.
Hu MM
1,
Yang Q
1,
Xie XQ
2,
Liao CY
2,
Lin H
3,
Liu TT
1,
Yin L
3,
Shu HB
4.
飞速体育cba:Author information
- 1College of Life Sciences, Wuhan University, Wuhan, China, 430072; Medical Research Institute, Wuhan University, Wuhan, China, 430072.
- 2Medical Research Institute, Wuhan University, Wuhan, China, 430072.
- 3College of Life Sciences, Wuhan University, Wuhan, China, 430072.
- 4College of Life Sciences, Wuhan University, Wuhan, China, 430072; Medical Research Institute, Wuhan University, Wuhan, China, 430072; Collaborative Innovation Center for Viral Immunology, Wuhan University, Wuhan, China, 430072. Electronic address: shuh@whu.edu.cn.
飞速体育cba:Abstract
During viral infection, sensing of cytosolic DNA by the cyclic GMP-AMP synthase (cGAS) activates the adaptor protein STING and triggers an antiviral response. Little is known about the mechanisms that determine the kinetics of activation and deactivation of thecGAS-STING pathway, ensuring effective but controlled innate antiviral responses. Here we found that the ubiquitin ligase Trim38 targets cGas for sumoylation in uninfected cells and during the early phase of viral infection. Sumoylation of cGas prevented its polyubiquitination and degradation. Trim38 also sumoylated Sting during the early phase of viral infection, promoting both Stingactivation and protein stability. In the late phase of infection, cGas and Sting were desumoylated by Senp2 and subsequently degraded via proteasomal and chaperone-mediated autophagy pathways, respectively. Our findings reveal an essential role for Trim38 in the innate immune response to DNA virus and provide insight into the mechanisms that ensure optimal activation and deactivation of the cGAS-STING pathway.
Copyright © 2016 Elsevier Inc. All rights reserved.
-
PMID:
-
27637147
-
DOI:
-
10.1016/j.immuni.2016.08.014
